此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

ExMI vs. Biofeedback PFMT for Post-Prostatectomy Incontinence

2026年7月7日 更新者:Abdullah Salah Al Debeiky、Tanta University

Effect of Extracorporeal Magnetic Stimulation Added to Pelvic Floor Muscle Training on Post-Prostatectomy Urine Incontinence: A Prospective Randomized Controlled Trial

This study looks at whether adding a non-invasive magnetic stimulation treatment to standard pelvic floor exercises helps men regain bladder control faster after prostate surgery (HoLEP or bipolar enucleation). Some men experience temporary urine leakage after this type of surgery. Participants will be randomly assigned to receive either pelvic floor muscle exercises alone, or pelvic floor muscle exercises combined with magnetic stimulation sessions using a specialized chair. Researchers will measure how long it takes for bladder control to return, how much urine leakage occurs, and how each treatment affects participants' quality of life over 6 months of follow-up.

研究概览

详细说明

This is a prospective, randomized controlled trial conducted at the outpatient urology clinic of Tanta University Hospital evaluating the effect of extracorporeal magnetic stimulation (ExMI) added to pelvic floor muscle training (PFMT) versus biofeedback-assisted PFMT alone on recovery of urinary continence following Holmium Laser Enucleation of the Prostate (HoLEP) or Bipolar Enucleation of the Prostate (BipoLEP) for benign prostatic hyperplasia.

A total of 100 male patients aged 50 years or older who develop postoperative stress-predominant urinary incontinence after catheter removal will be randomized in a 1:1 ratio to Group 1 (electromagnetic pelvic floor stimulation, n=50) or Group 2 (biofeedback-assisted pelvic floor muscle training, n=50).

All participants will receive supervised PFMT consisting of three daily sessions (10 slow contractions of 5-10 seconds and 10 rapid contractions per session) for 12 weeks postoperatively. Group 1 will additionally receive extracorporeal magnetic stimulation using a magnetic chair device, twice weekly for 20-30 minutes per session over 6-8 weeks, at an intensity adjusted to patient tolerance, aiming to induce repetitive pelvic floor muscle contraction and pudendal nerve stimulation.

Continence status will be assessed after catheter removal and at follow-up visits at 2 weeks, 1 month, 3 months, and 6 months postoperatively, using pad count, 24-hour pad weight testing, the ICIQ-UI SF questionnaire, and quality-of-life scoring. Continence will be defined as no pad use, or use of one security pad with no significant leakage.

The primary outcome is time to recovery of urinary continence. Secondary outcomes include reduction in pad usage, improvement in 24-hour pad test results, improvement in ICIQ-UI SF score, quality-of-life improvement, and treatment-related adverse events.

研究类型

介入性

注册 (估计的)

100

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Tanta、埃及、31111
        • Tanta University Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Male patients aged ≥50 years
  • Diagnosed with symptomatic benign prostatic hyperplasia (BPH) requiring surgical intervention
  • Scheduled for Holmium Laser Enucleation of the Prostate (HoLEP) or Bipolar Enucleation of the Prostate (BipoLEP)
  • Development of postoperative stress-predominant urinary incontinence after catheter removal
  • Presence of postoperative urinary leakage requiring at least one safety pad/day
  • Ability to understand and perform pelvic floor muscle training instructions
  • Ability and willingness to attend extracorporeal magnetic stimulation sessions and follow-up visits

Exclusion Criteria:

  • Preoperative urinary incontinence or neurogenic bladder dysfunction
  • Previous prostate surgery or prior anti-incontinence surgery
  • Urethral stricture disease or bladder neck contracture
  • Active urinary tract infection at the time of enrollment
  • Severe cognitive impairment preventing compliance with PFMT instructions
  • Neurological disorders affecting lower urinary tract function, including Parkinson disease, multiple sclerosis, spinal cord injury, or cerebrovascular stroke with residual deficits
  • Implanted electronic or metallic devices contraindicating magnetic stimulation, including cardiac pacemaker, implantable cardioverter-defibrillator, neurostimulators, or cochlear implants
  • Uncontrolled diabetes mellitus with severe neuropathy
  • Receiving concurrent therapies for urinary incontinence during the study period
  • Persistent postoperative complications requiring reintervention (e.g., severe hematuria, clot retention)
  • Inability or refusal to complete follow-up evaluations

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Electromagnetic Pelvic Floor Stimulation (ExMI + PFMT)
Patients receive standard pelvic floor muscle training (three daily sessions, each with 10 slow contractions of 5-10 seconds and 10 rapid contractions, continued for 12 weeks postoperatively) plus extracorporeal magnetic stimulation using a magnetic chair device, administered twice weekly for 20-30 minutes per session over 6-8 weeks, at an intensity adjusted to patient tolerance.
Non-invasive pelvic floor and pudendal nerve stimulation delivered via a magnetic chair device, twice weekly for 20-30 minutes per session over 6-8 weeks.
Supervised pelvic floor muscle training consisting of three daily sessions (10 slow contractions of 5-10 seconds and 10 rapid contractions per session), continued for 12 weeks postoperatively, with biofeedback assistance.
有源比较器:Biofeedback-Assisted Pelvic Floor Muscle Training
Patients receive standard pelvic floor muscle training (three daily sessions, each with 10 slow contractions of 5-10 seconds and 10 rapid contractions, continued for 12 weeks postoperatively) with biofeedback assistance, without extracorporeal magnetic stimulation.
Supervised pelvic floor muscle training consisting of three daily sessions (10 slow contractions of 5-10 seconds and 10 rapid contractions per session), continued for 12 weeks postoperatively, with biofeedback assistance.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Time to Recovery of Urinary Continence
大体时间:Up to 6 months postoperatively
Continence is defined as no pad use or use of one security pad with no significant leakage. Time from catheter removal to achievement of continence will be recorded for each participant.
Up to 6 months postoperatively

次要结果测量

结果测量
措施说明
大体时间
Change in Pad Usage
大体时间:Baseline (after catheter removal), 2 weeks, 1 month, 3 months, and 6 months postoperatively
Number of pads used per day, assessed at each follow-up visit.
Baseline (after catheter removal), 2 weeks, 1 month, 3 months, and 6 months postoperatively
Change in 24-Hour Pad Test Result
大体时间:Baseline (after catheter removal), 2 weeks, 1 month, 3 months, and 6 months postoperatively
Objective urine leakage measured in grams over a 24-hour period.
Baseline (after catheter removal), 2 weeks, 1 month, 3 months, and 6 months postoperatively
Change in ICIQ-UI SF Score
大体时间:Baseline (after catheter removal), 2 weeks, 1 month, 3 months, and 6 months postoperatively
International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form score, assessing severity and impact of urinary incontinence.
Baseline (after catheter removal), 2 weeks, 1 month, 3 months, and 6 months postoperatively
Change in Quality of Life (QoL) Score
大体时间:Baseline (after catheter removal), 2 weeks, 1 month, 3 months, and 6 months postoperatively
Quality of life score assessed at each follow-up visit.
Baseline (after catheter removal), 2 weeks, 1 month, 3 months, and 6 months postoperatively
Incidence of Treatment-Related Adverse Events
大体时间:Up to 6 months postoperatively
Number and type of complications or adverse events related to pelvic floor muscle training or extracorporeal magnetic stimulation.
Up to 6 months postoperatively

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Esraa Abdelhamid Elshintenawy, MD、Tanta University Faculty of Medicine
  • 首席研究员:Mona Helal Omara, MD、Tanta University Faculty of Medicine

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年7月1日

初级完成 (估计的)

2027年6月1日

研究完成 (估计的)

2027年6月1日

研究注册日期

首次提交

2026年7月7日

首先提交符合 QC 标准的

2026年7月7日

首次发布 (实际的)

2026年7月13日

研究记录更新

最后更新发布 (实际的)

2026年7月13日

上次提交的符合 QC 标准的更新

2026年7月7日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅